<div><div></div><div><span><p><strong><span>Cor appointed Brent Pfeiffenberger to its board of directors as an independent director, effective May 13, 2026.</span></strong></p><div><table><tbody><tr><td><span>Individual</span></td><td><span>Brent Pfeiffenberger</span></td></tr><tr><td><span>Role</span></td><td><span>Member of the Board (independent)</span></td></tr><tr><td><span>Type of Change</span></td><td><span>Appointed</span></td></tr><tr><td><span>Effective Date</span></td><td><span>May 13, 2026</span></td></tr><tr><td><span>Reason</span></td><td><span>Appointment by Board recommendation of Nominating and Corporate Governance Committee</span></td></tr><tr><td><span>Replacement Info</span></td><td><span>Not disclosed</span></td></tr><tr><td><span>Background Details</span></td><td><span>President &amp; CEO and director of Century Therapeutics since Dec 2023; chairman since Aug 2025; prior COO of Neogene Therapeutics (May 2021–Dec 2023); prior senior roles at Bristol-Myers Squibb; MBA (Wharton) and Pharm.D. (Duquesne)</span></td></tr><tr><td><span>Board/Committee Role Changes</span></td><td><span>Not disclosed</span></td></tr></tbody></table></div><p><span>Original SEC Filing: </span>Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] - 8-K - May. 14, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

IPSC

<p>Cor has appointed Brent Pfeiffenberger as an independent director on its board, effective May 13, 2026. Pfeiffenberger is currently the President & CEO of Century Therapeutics and has held senior roles at Neogene Therapeutics and Bristol-Myers Squibb. The appointment follows a recommendation from the Nominating and Corporate Governance Committee. Further details regarding board role changes were not disclosed.</p>

Cor appoints Brent Pfeiffenberger to board as independent director